Advanced Oncotherapy (AVO) – Appointment of Senior Vice-President of Medical Physics
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces the appointment of Dr. Jonathan Farr as Senior Vice-President of Medical Physics with immediate effect. Dr. Farr will not be taking a Board position. Dr. Farr is a medical physicist working in the treatment of cancer, specialising in proton therapy. His experience […]
AVO – Give me some LIGHT – Wall Street Wires
by Spekulator at Wall Street Wires An introduction. I am an active investor into smaller companies where I see (a) genuine value (b) good management (c) an unusual or groundbreaking product. Mostly a,b and c have to be present and correct, but I will make exceptions. I am invested into companies listed on Nasdaq, London […]
Advanced Oncotherapy (AVO) – Additional financing agreement and new appointment
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces it has made further progress in attracting personnel at the forefront of their field and additional financing. Additional Financing Advanced Oncotherapy announces, that on 12 June 2017, it has entered into a further loan agreement with Blackfinch Investment Ltd, through its […]
Advanced Oncotherapy (AVO) – Technological milestones update
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces further notable progress in the manufacture of its first LIGHT system. Patient Positioning System Multiple components of the treatment room have been manufactured, inspected and tested by the Company’s partner P-Cure Ltd., ahead of their integration to form a complete […]
Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers, Start of Treatment, Specifications & Company Analysis – Global Forecast to 2022
ReportsWorldwide has announced the addition of a new report title Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers, Start of Treatment, Specifications & Company Analysis – Global Forecast to 2022 to its growing collection of premium market research reports. The continuing exploration of the benefits of proton therapy is inspiring […]
Advanced Oncotherapy (AVO)- Bracknor waives requirement to call a General Meeting
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that following discussions with the Company, Bracknor Investment Group has waived the requirement to call a General Meeting proposing a reduction in the nominal value of ordinary shares of 25p each, as had been stipulated in the Circular for the […]
Advanced Oncotherapy (AVO) – Holdings in company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may […]
Advanced Oncotherapy (AVO) – Harley Street construction update
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that excavation work at its flagship Harley Street site is progressing well and on time. Work has been completed on multiple stages of site work and demolition activity, with groundworks and piling, the longest stage in the excavation and build process […]
Advanced Oncotherapy (AVO) – Conversion of convertible loan notes
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the Convertible Loan Notes into new ordinary shares of 25p each in the share capital of the Company. Further details of the conversion are set out […]
Advanced Oncotherapy (AVO) – Update on Bracknor financing
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has drawn down the third tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche), for proceeds of £1.235 million. Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, […]